Disease · EFO_1000653

sarcopenia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sarcopenia. Diseases, record EFO_1000653. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1000653

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sarcopenia; Open Targets
Open Targets ID: EFO_1000653; Open Targets
Other names: sarcopenias; Open Targets
MeSH: D055948; MeSH
Highest stage of its drugs: Phase 3, for 5 of its 31 drugs, from ClinicalTrials.gov; Open Targets

Drugs31

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AMINO ACIDS	CHEMBL1201498		Phase 3	ClinicalTrials.gov	5	5	2	Drugs and targets
DENOSUMAB	CHEMBL1237023	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PRASTERONE	CHEMBL90593	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METFORMIN HYDROCHLORIDE	CHEMBL1703	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SOMATROPIN	CHEMBL1201621	Protein	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
BIMAGRUMAB	CHEMBL3137353	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
TESTOSTERONE	CHEMBL386630	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
20-HYDROXYECDYSONE	CHEMBL224128	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CREATINE	CHEMBL283800	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 31

See all 31 drugs

Targets65

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AR	Androgen receptor	4	Androgen Receptor agonist; Androgen Receptor modulator	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/56901	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	2	Gonadotropin-releasing hormone receptor agonist	Unknown	https://conductscience.org/library/genes/2798	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	2	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 3	https://conductscience.org/library/genes/2820	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4537	Drugs and targets
MT-ND4	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4538	Drugs and targets
MT-ND4L	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4539	Drugs and targets

1 to 10 of 65

See all 65 targets

Trials32

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03452488	A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)	Phase 2	233	2024-10-01	Sarcopenia, Gait Disorders in Old Age, Muscle Weakness	20-HYDROXYECDYSONE	Its record names the disease	ClinicalTrials.gov
NCT02333331	Dose Range Finding Study of Bimagrumab in Sarcopenia	Phase 2	217	2019-08-06	Sarcopenia	BIMAGRUMAB	Its record names the disease	ClinicalTrials.gov
NCT00529659	A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)	Phase 2	170	2012-07-02	Sarcopenia	MK-0773	Its record names the disease	ClinicalTrials.gov
NCT02468674	A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study	Phase 2	160	2019-12-09	Sarcopenia	BIMAGRUMAB	Its record names the disease	ClinicalTrials.gov
NCT02308228	Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)	Early phase 1	109	2019-09-17	Aging	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT00957528	Cycled Testosterone Replacement Study	Phase 1	26	2012-08-21	Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT01963598	Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia	Phase 2	253		Sarcopenia	TREVOGRUMAB	Its record names the disease	ClinicalTrials.gov
NCT05978206	Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet	Phase 2	168		Sarcopenia	NANDROLONE DECANOATE	Its record names the disease	ClinicalTrials.gov
NCT03784495	Melatonin Plus Aminoacids for Sarcopenic Elderly	Not applicable	159		Sarcopenia	AMINO ACIDS, MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT00111930	Biological Effects of Dehydroepiandrosterone (DHEA) in the Elderly	Not applicable	144		Healthy	PRASTERONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 32

See all 32 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
MK-0773 vs Placebo: serious adverse events	12 of 81	9 of 89	170	NCT00529659	Trial comparisons
Metformin vs Placebo, Sugar Pill: deaths from any cause	0 of 54	0 of 55	109	NCT02308228	Trial comparisons
Metformin vs Placebo, Sugar Pill: serious adverse events	0 of 54	0 of 55	109	NCT02308228	Trial comparisons

Papers from its trials28

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40381110	RESULT	1	PubMed
39084052	RESULT	1	PubMed
38263952	RESULT	1	PubMed
36594428	RESULT	1	PubMed
32829751	RESULT	1	PubMed
32150289	RESULT	1	PubMed
24737557	RESULT	1	PubMed
23732550	RESULT	1	PubMed
21475673	RESULT	1	PubMed
18812486	RESULT	1	PubMed

1 to 10 of 28

See all 28 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1000653

GET https://conductscience.org/api/diseases/v1/EFO_1000653/drugs?page=2

API reference For AI assistants